---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-103731"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-09-05T23:59:59+00:00"
generated_at: "2026-05-31T06:20:31.590984+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track Designation for Perspective's VMT01 in MC1R-positive melanoma

## Summary
- Fast Track for 212Pb VMT01: diagnosis and treatment of unresectable or metastatic MC1R-positive melanoma.
- Designation enables more frequent FDA interactions and eligibility for accelerated/priority/rolling review.
- Phase 1/2a Cohort 2 DLT observation period completed; safety data to be shared with SMC and scientific forum.
- Company plans to open VMT01/anti-PD-1 combination cohort pending IRB approval.

## SEC filing metadata
- accession: 0000950170-24-103731
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-09-05T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017024103731/0000950170-24-103731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017024103731/catx-20240905.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-103731
- JSON: https://secwatch.observer/filing/0000950170-24-103731.json
- Plain text: https://secwatch.observer/filing/0000950170-24-103731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.